{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:56Z","timestamp":1786119356825,"version":"build-2736575974"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1097\/mjt.0b013e318192116f","type":"journal-article","created":{"date-parts":[[2009,11,14]],"date-time":"2009-11-14T03:18:26Z","timestamp":1258168706000},"page":"579-584","source":"Crossref","is-referenced-by-count":10,"title":["Antiretroviral Therapy With Heart"],"prefix":"10.1097","volume":"16","author":[{"given":"Paul","family":"Randell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Moyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-19-20210202","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0140-6736(03)13802-0","article-title":"Decline in the AIDS and death rates in the EuroSIDA study: an observational study.","volume":"362","author":"Mocroft","year":"2003","journal-title":"Lancet"},{"key":"R2-19-20210202","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/00002030-200305230-00010","article-title":"Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study.","volume":"17","author":"Friis-Moller","year":"2003","journal-title":"AIDS"},{"key":"R3-19-20210202","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa062744","article-title":"Class of antiretroviral drugs and the risk of myocardial infarction.","volume":"356","year":"2007","journal-title":"N Engl J Med"},{"key":"R4-19-20210202","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc07-2013","article-title":"Incidence and risk factors for new-onset diabetes in HIV-infected patients.","volume":"31","author":"DeWit","year":"2008","journal-title":"Diabetes Care"},{"key":"R5-19-20210202","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","article-title":"D:A:D Study Group, Sabin C, Worm S, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.","volume":"371","year":"2008","journal-title":"Lancet"},{"key":"R6-19-20210202","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2796.2006.01761.x","article-title":"HAART and the heart: changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapy.","volume":"261","author":"Sterne","year":"2007","journal-title":"J Intern Med"},{"key":"R7-19-20210202","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1001\/jama.289.22.2978","article-title":"Impact of HIV Infection and HAART on serum lipids in men.","volume":"289","author":"Riddler","year":"2003","journal-title":"JAMA"},{"key":"R8-19-20210202","first-page":"1045","article-title":"Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.","volume":"74","author":"Grunfeld","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"R9-19-20210202","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/QAI.0b013e31816d9ba1","article-title":"The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men.","volume":"48","author":"Wohl","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R10-19-20210202","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa062360","article-title":"CD4+ count-guided interruption of antiretroviral treatment.","volume":"355","year":"2006","journal-title":"N Engl J Med"},{"key":"R12-19-20210202","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1258\/000456307780945778","article-title":"The biochemical assessment of insulin resistance.","volume":"44","author":"Borai","year":"2007","journal-title":"Ann Clin Biochem"},{"key":"R13-19-20210202","first-page":"E214","article-title":"Glucose clamp technique: a method for quantifying insulin secretion and resistance.","volume":"237","author":"DeFronzo","year":"1979","journal-title":"Am J Physiol"},{"key":"R14-19-20210202","doi-asserted-by":"crossref","first-page":"E1666","DOI":"10.1152\/ajpendo.00550.2006","article-title":"Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults.","volume":"292","author":"Fleischman","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R15-19-20210202","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/00002030-200203290-00002","article-title":"Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study.","volume":"16","author":"Noor","year":"2002","journal-title":"AIDS"},{"key":"R16-19-20210202","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1086\/505974","article-title":"Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers.","volume":"43","author":"Lee","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R17-19-20210202","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1097\/01.aids.0000244200.11006.55","article-title":"Effects of atazanavir\/ritonavir and lopinavir\/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically.","volume":"20","author":"Noor","year":"2006","journal-title":"AIDS"},{"key":"R18-19-20210202","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1097\/00002030-200411050-00005","article-title":"The effects of HIV protease inhibitors atazanavir and lopinavir\/ritonavir on insulin sensitivity in HIV-seronegative healthy adults.","volume":"18","author":"Noor","year":"2004","journal-title":"AIDS"},{"key":"R19-19-20210202","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1097\/QAD.0b013e32826fbc54","article-title":"Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers.","volume":"21","author":"Lee","year":"2007","journal-title":"AIDS"},{"key":"R20-19-20210202","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00002030-200105040-00001","article-title":"Metabolic effects of indinavir in healthy HIV-seronegative men.","volume":"15","author":"Noor","year":"2001","journal-title":"AIDS"},{"key":"R21-19-20210202","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/00002030-200403050-00008","article-title":"The metabolic effects of lopinavir\/ritonavir in HIV-negative men.","volume":"18","author":"Lee","year":"2004","journal-title":"AIDS"},{"key":"R22-19-20210202","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/QAD.0b013e3282f33557","article-title":"Zidovudine\/lamivudine contributes to insulin resistance within 3 months of starting antiretroviral therapy.","volume":"22","author":"Blumer","year":"2008","journal-title":"AIDS"},{"issue":"27","key":"R25-19-20210202","doi-asserted-by":"crossref","first-page":"20251","DOI":"10.1074\/jbc.C000228200","article-title":"The mechanism of insulin resistance caused by HIV protease inhibitor therapy.","volume":"275","author":"Murata","year":"2000","journal-title":"J Biol Chem"},{"key":"R26-19-20210202","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.2337\/diabetes.50.6.1378","article-title":"The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance.","volume":"50","author":"Caron","year":"2001","journal-title":"Diabetes"},{"key":"R27-19-20210202","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1097\/00002030-200208160-00003","article-title":"Indinavir inhibits sterol-regulatory element-binding protein-1c-dependent lipoprotein lipase and fatty acid synthase gene activations.","volume":"16","author":"Miserez","year":"2002","journal-title":"AIDS"},{"key":"R28-19-20210202","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1097\/QAD.0b013e3283021a4f","article-title":"Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes.","volume":"22","author":"Jones","year":"2008","journal-title":"AIDS"},{"key":"R29-19-20210202","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1161\/CIRCRESAHA.107.165472","article-title":"Role of mitochondrial dysfunction in insulin resistance.","volume":"102","author":"Kim","year":"2008","journal-title":"Circ Res"},{"key":"R30-19-20210202","first-page":"155","article-title":"The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT).","volume":"86","author":"Moyle","year":"1993","journal-title":"Q J Med"},{"key":"R31-19-20210202","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1086\/381783","article-title":"Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?","volume":"189","author":"Fontas","year":"2004","journal-title":"J Infect Dis"},{"key":"R33-19-20210202","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/QAI.0b013e31815acab8","article-title":"Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine\/lamivudine and efavirenz in treatment-naive patients.","volume":"47","author":"Arribas","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R34-19-20210202","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients.","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"R35-19-20210202","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1097\/01.aids.0000247574.33998.03","article-title":"A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.","volume":"20","author":"Moyle","year":"2006","journal-title":"AIDS"},{"key":"R36-19-20210202","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1371\/journal.pmed.0010019","article-title":"Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.","volume":"1","author":"vanLeth F, Phanuphak","year":"2004","journal-title":"PLoS Med"},{"key":"R37-19-20210202","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/QAI.0b013e31802bf122","article-title":"Less lipoatrophy and better lipid profile with abacavir as compared to stavudine.","volume":"44","author":"Podzamczer","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R38-19-20210202","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1086\/517497","article-title":"Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.","volume":"44","author":"Gatell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R40-19-20210202","first-page":"174","article-title":"Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia.","volume":"39","author":"Mobius","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R41-19-20210202","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1468-1293.2007.00541.x","article-title":"Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen.","volume":"9","author":"Colafigli","year":"2008","journal-title":"HIV Med"},{"key":"R42-19-20210202","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/jac\/dkm413","article-title":"Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.","volume":"61","author":"Soriano","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R43-19-20210202","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/00002030-200207050-00010","article-title":"Reversal of atherogenic lipoprotein profile in HIV-1-infected patients with lipodystrophy after replacing protease inhibitors by nevirapine.","volume":"16","author":"Negredo","year":"2002","journal-title":"AIDS"},{"key":"R44-19-20210202","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"R45-19-20210202","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines.","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"R46-19-20210202","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/j.ahj.2003.10.018","article-title":"Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors.","volume":"147","author":"Stein","year":"2004","journal-title":"Am Heart J"},{"key":"R47-19-20210202","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/00002030-200203080-00008","article-title":"Pharmacokinetic interactions between protease inhibitors and statins in HIV-seronegative volunteers: ACTG Study A5047.","volume":"16","author":"Fichtenbaum","year":"2002","journal-title":"AIDS"},{"key":"R48-19-20210202","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/01.qai.0000167156.44980.33","article-title":"Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin.","volume":"39","author":"Gerber","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R49-19-20210202","first-page":"361","article-title":"Martin, Vandhuick O, Guillo P, et al.","volume":"185","year":"2006","journal-title":"Premature atherosclerosis in HIV-positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study) Atherosclerosis"},{"key":"R50-19-20210202","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1097\/01.aids.0000171406.53737.f9","article-title":"Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure.","volume":"19","author":"Currier","year":"2005","journal-title":"AIDS"},{"key":"R51-19-20210202","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.mca.0000236292.86930.e3","article-title":"An ultrasound-based comparative study on carotid plaques in HIV-positive patients vs. atherosclerotic and arteritis patients: atherosclerotic or inflammatory lesions?","volume":"18","author":"Maggi","year":"2007","journal-title":"Coron Artery Dis"},{"key":"R52-19-20210202","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/QAD.0b013e3282f560d9","article-title":"Association of antiretroviral therapy with fibrinogen levels in HIV-infection.","volume":"22","author":"Madden","year":"2008","journal-title":"AIDS"},{"key":"R53-19-20210202","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/MOL.0b013e3282ef604f","article-title":"How HIV protease inhibitors promote atherosclerotic lesion formation.","volume":"18","author":"Thomas","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"R54-19-20210202","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/QAI.0b013e3180322542","article-title":"Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction.","volume":"44","author":"Wang","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R55-19-20210202","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1468-1293.2006.00362.x","article-title":"The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study.","volume":"7","author":"Law","year":"2006","journal-title":"HIV Med"},{"key":"R57-19-20210202","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00126334-200211010-00001","article-title":"Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA Panel.","volume":"31","author":"Schambelan","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R58-19-20210202","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1468-1293.2007.00534.x","article-title":"European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV.","volume":"9","author":"Lundgren","year":"2008","journal-title":"HIV Med"},{"key":"R59-19-20210202","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1468-1293.2006.00424.x","article-title":"British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).","volume":"7","year":"2006","journal-title":"HIV Med"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00045391-200911000-00019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:03:18Z","timestamp":1786039398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00045391-200911000-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e318192116f","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}